Dyne Therapeutics (NASDAQ:DYN) Rating Lowered to Sell at StockNews.com

StockNews.com downgraded shares of Dyne Therapeutics (NASDAQ:DYN) from a hold rating to a sell rating in a report issued on Monday morning.

DYN has been the subject of several other research reports. Jefferies Financial Group raised their target price on shares of Dyne Therapeutics from $36.00 to $42.00 and gave the stock a buy rating in a research note on Monday, May 20th. Morgan Stanley raised their price objective on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the company an overweight rating in a research report on Wednesday, August 14th. HC Wainwright reiterated a buy rating and set a $55.00 target price on shares of Dyne Therapeutics in a research report on Wednesday, September 4th. Guggenheim increased their target price on Dyne Therapeutics from $45.00 to $50.00 and gave the stock a buy rating in a research note on Thursday, August 15th. Finally, Chardan Capital lifted their price target on Dyne Therapeutics from $31.00 to $42.00 and gave the company a buy rating in a research note on Tuesday, May 21st. One analyst has rated the stock with a sell rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and a consensus price target of $51.40.

Dyne Therapeutics Stock Down 0.8 %

DYN opened at $34.34 on Monday. Dyne Therapeutics has a 52 week low of $6.40 and a 52 week high of $47.45. The business has a 50 day moving average price of $41.38 and a two-hundred day moving average price of $33.47. The company has a market cap of $3.00 billion, a PE ratio of -8.65 and a beta of 1.07.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Monday, August 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.02. As a group, sell-side analysts expect that Dyne Therapeutics will post -2.96 EPS for the current fiscal year.

Insider Buying and Selling

In related news, COO Susanna Gatti High sold 29,787 shares of Dyne Therapeutics stock in a transaction on Friday, June 21st. The stock was sold at an average price of $35.01, for a total transaction of $1,042,842.87. Following the completion of the transaction, the chief operating officer now directly owns 148,792 shares of the company’s stock, valued at $5,209,207.92. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, COO Susanna Gatti High sold 29,787 shares of the stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $35.01, for a total value of $1,042,842.87. Following the sale, the chief operating officer now directly owns 148,792 shares of the company’s stock, valued at approximately $5,209,207.92. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO John Cox bought 32,000 shares of the business’s stock in a transaction on Wednesday, September 4th. The shares were acquired at an average price of $33.04 per share, with a total value of $1,057,280.00. Following the transaction, the chief executive officer now owns 8,000 shares of the company’s stock, valued at approximately $264,320. The disclosure for this purchase can be found here. Insiders own 20.77% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Nisa Investment Advisors LLC grew its holdings in Dyne Therapeutics by 904.1% during the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock valued at $26,000 after buying an additional 669 shares during the last quarter. Amalgamated Bank lifted its position in shares of Dyne Therapeutics by 39.9% in the second quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock valued at $99,000 after acquiring an additional 796 shares in the last quarter. Ameritas Investment Partners Inc. lifted its position in shares of Dyne Therapeutics by 28.0% in the first quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company’s stock valued at $167,000 after acquiring an additional 1,291 shares in the last quarter. Public Employees Retirement Association of Colorado acquired a new stake in shares of Dyne Therapeutics during the second quarter valued at $203,000. Finally, Farallon Capital Management LLC purchased a new stake in Dyne Therapeutics during the 2nd quarter worth about $212,000. 96.68% of the stock is currently owned by institutional investors and hedge funds.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.